JO
XLO icon

John Overdeck’s Xilio Therapeutics XLO Stock Holding History

John Overdeck’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$139K Buy
+14,544
New +$121K ﹤0.01% 4845
2026
Q1 		– Sell
-4,431
Closed -$39.7K – 4965
2025
Q4 		$39.7K Sell
4,431
-1,840
-29% -$19.3K ﹤0.01% 3956
2025
Q3 		$74K Buy
6,271
+697
+13% +$6.98K ﹤0.01% 3506
2025
Q2 		$53.1K Sell
5,574
-431
-7% -$4.55K ﹤0.01% 3060
2025
Q1 		$60.9K Buy
6,005
+5,232
+677% +$65.8K ﹤0.01% 3028
2024
Q4 		$10.3K Buy
773
+31
+4% +$426 ﹤0.01% 3134
2024
Q3 		$8.18K Buy
+742
New +$9.11K ﹤0.01% 3053

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

John Overdeck's XLO Position: Q2 2026 in Review

John Overdeck opened a new position in Xilio Therapeutics (XLO) in Q2 2026: 14,544 shares worth $139K. The stake represents ﹤0.01% of the portfolio and ranks #4845 among its holdings. This is a return to the name: John Overdeck previously reported a position in XLO as recently as Q4 2025.

John Overdeck first reported a position in XLO in Q3 2024 and has held it in 7 quarters since. 26 funds tracked by Wall St. Rank hold XLO as of Q2 2026.

  • John Overdeck held 14,544 shares of Xilio Therapeutics worth $139K as of Q2 2026.
  • Xilio Therapeutics was a new John Overdeck position in Q2 2026.
  • Xilio Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4845 holding.
  • John Overdeck first reported a position in Xilio Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 26 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.